Multiantivirus compound, composition and method for treatment of virus diseases
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-8722642-B2
Publication Date
2014-05-13
Expiration Date
Abstract
A method for obtaining a new antiviral compound with multiple action against many viruses, comprising modified highly purified yeast RNA, a pharmaceutical composition comprising such RNA, and a method for the treatment and prevention of viral disease comprising administering to a patient a composition comprising an amount effective to ameliorate the symptoms of viral disease of ribonucleic acid. The exogenous modified yeast RNA has a pronounced multiple anti-virus action in a wide range of concentrations. The modified yeast RNA is capable of inhibiting the reproduction of viruses from Orthomyxoviridae, Paramyxovirus, Hepatitis, Herpesviridae families, enterovirus and adenovirus. Also, the modified yeast RNA is capable of inhibiting the reproduction of influenza viruses, hepatitis C virus, genital herpes, human immunodeficiency virus and Coxsackie B virus.
Core Innovation
The invention relates to a composition for preventing or treating an infection by a virus. The composition comprises a purified yeast RNA extract combined with mannitol, where the yeast RNA extract contains nucleotide fragments having 25±10 nucleotides and a purity degree of at least 99% by weight. The yeast RNA extract and mannitol are present in a proportion of about 2:1 to about 3:1 by weight, and the RNA extract constitutes at least about 50% by weight of the composition.
The document addresses the need for antivirals acting against multiple virus families and describes antiviral activity across a broad range of viruses and viral families. Examples include influenza, hepatitis C virus (HCV), genital herpes/HSV-2, human immunodeficiency virus (HIV), Coxsackie B, enteroviruses, and adenovirus, as well as orthomyxovirus/paramyxovirus and herpesviridae.
For the RNA-mannitol approach, the document summarizes preclinical and comparative observations including in vitro and in vivo efficacy metrics. It reports antiviral activity in cell culture and surrogate models, including an influenza pneumonia mouse model and models described for HCV and genital herpes, and describes inhibition of neuraminidase/hemagglutinin, induction of alpha-interferon, and inhibition related to virus receptors that enable virus replication in cells.
Claims Coverage
The independent claim coverage is directed to a virus-preventing or virus-treating composition defined by a purified yeast RNA extract fragment size, high purity, and a specific weight proportion with mannitol. The inventive features involve the defined RNA fragment characteristics, the high purity degree, the RNA-to-mannitol ratio, and the requirement that the RNA extract constitutes at least about half of the composition.
Purified yeast RNA extract with defined fragment size and high purity
A purified RNA extract comprising nucleotide fragments having 25±10 nucleotides with a purity degree of at least 99% by weight.
RNA-mannitol combination with defined weight proportion
The yeast RNA extract and mannitol are present in the composition in a proportion of from about 2:1 to about 3:1 by weight.
RNA extract constitutes at least about half the composition
The RNA extract constitutes at least about 50% by weight of the composition.
Preventing or treating viral infection
A composition for preventing or treating an infection by a virus.
Overall, the claims center on a composition combining purified yeast RNA extract and mannitol, where the RNA extract is defined by 25±10 nucleotide fragments and at least 99% purity by weight, present at about 2:1 to about 3:1 by weight with mannitol, and comprising at least about 50% by weight of the composition for preventing or treating viral infections.
Stated Advantages
Provides broad inhibition across multiple virus families and viruses described in the document.
Reported antiviral activity in vitro and in vivo, including outcomes summarized using measures such as MEC, MAC, and chemotherapeutic indices for RNA-M.
Documented reduction in pathology in antiherpetic activity models described in the document.
Includes comparative clinical observations in ARVI/influenza patients versus Tamiflu plus observations in HCV and genital herpes patients described in the document.
Documented Applications
Preventing or treating infections by viruses, including influenza, HCV, genital herpes/HSV-2, HIV, Coxsackie B, enteroviruses, adenovirus, orthomyxovirus/paramyxovirus, and herpesviridae as described in the document.
Use in ARVI/influenza patient observations compared against Tamiflu as described in the document.
Use in HCV and genital herpes patient observations described in the document.
Use in described animal and cell models including an influenza pneumonia mouse model and a guinea pig genital herpes model, as well as surrogate models described for HCV.
Interested in licensing this patent?